Pulsenmore Strengthens U.S. Commercial Leadership, Appoints Med-Tech Veteran David Woods as Chief Commercial Officer
U.S. commercial operations follow FDA authorization of Pulsenmore's home prenatal ultrasound system.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Pulsenmore (PLSM) appointed David Woods as Chief Commercial Officer and expanded its U.S. commercial team as it builds its healthcare-market presence.
Woods brings more than 25 years of medtech leadership experience, most recently as Chief Commercial Officer at Creo Medical. He previously served as President and CEO of PENTAX Medical Americas. Pulsenmore has launched U.S. commercial operations following FDA De Novo authorization of its home prenatal ultrasound system and entered a collaboration with Ouma Health. The company is exploring opportunities associated with the federal Rural Health Transformation Program as part of its U.S. growth strategy.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Major pointFDA De Novo authorization secured for the home prenatal ultrasound system.
- Moderate pointU.S. commercial operations launched following FDA authorization.
- Moderate pointU.S. commercial team expansion supports the company's stated growth strategy.
- Minor pointRural Health Transformation Program opportunities are being explored as part of the company's U.S. growth strategy.
Negative
- None.
Details
Market move: PLSM +4.40% in the Oct 13 session. Chief commercial officer appointment
On Oct 13, the day this news came out, PLSM closed 4.40% above the previous close. Relative volume reached 3.2x the daily average during tracking.
Data tracked by StockTitan Argus for the Oct 13 session.
Historical Context
-
Prior results documented the U.S. launch, provider agreements, and Ouma partnership before this team expansion.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
de novo authorization regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Expanded commercial team to accelerate
RAMAT GAN,
David Woods brings more than 25 years of medtech leadership experience, most recently serving as CCO at Creo Medical. Previously, he held senior executive roles at PENTAX Medical, including President and CEO of PENTAX Medical Americas.
Following FDA De Novo authorization of its home prenatal ultrasound system, Pulsenmore has launched
Pulsenmore sees significant commercial potential in addressing gaps in maternal care access, particularly in underserved and rural communities. As part of its
"We believe the U.S. market presents a significant opportunity for Pulsenmore, with growing recognition of the need to bring maternal care closer to patients," said Dr. Elazar Sonnenschein, CEO and founder of Pulsenmore. "Our commercial progress, together with new investments in rural healthcare, reinforces our commitment to this market. Expanding our commercial team and bringing David on board reflect our focus on translating this opportunity into sustainable growth."
"I'm excited to join Pulsenmore and support its commitment to advancing women's health. Bringing ultrasound into the home has the potential to make maternal care more accessible and connected, helping women feel informed and supported throughout their pregnancies. I look forward to contributing my experience to help expand that impact," said David Woods, incoming Chief Commercial Officer of Pulsenmore.
About Pulsenmore
Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM) is a healthcare technology company focused on transforming women's healthcare through remote ultrasound and telemedicine solutions. The Company develops patient-operated ultrasound systems that enable remote clinical assessment and monitoring, with applications across pregnancy and fertility care.
Forward-Looking Statements
This press release contains forward-looking statements. In particular, statements using words such as "may," "seek," "will," "consider," "likely," "assume," "estimate," "expect," "anticipate," "intend," "believe," "contemplate," "do not believe," "aim," "goal," "due," "predict," "plan," "project," "continue," "potential," "positioned," "guidance," "objective," "outlook," "trends," "future," "could," "would," "should," "target," "on track" or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. Such forward-looking statements include, but are not limited to, statements regarding the Company's plans to expand its commercial organization and scale its presence in the U.S. healthcare market; the expected contributions of David Woods and the Company's expanded commercial team to the Company's growth strategy; the commercialization, market adoption and potential benefits of the Company's home prenatal ultrasound system and remote monitoring platform; the Company's strategic collaboration with Ouma Health; the Company's ability to expand access to prenatal and maternal care, including in underserved and rural communities; opportunities that may arise from the federal Rural Health Transformation Program and other investments in rural healthcare; and the potential size, growth and commercial opportunities of the U.S. maternal healthcare market.
Forward-looking statements reflect Pulsenmore's current views, plans, or expectations with respect to future events or financial performance. They are inherently subject to significant business, economic, competitive, and other risks, uncertainties, and contingencies. Forward-looking statements are based on Pulsenmore's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including, but not limited to, the following: the Company's lack of operating history; the Company's current and future capital requirements and the Company's belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company's ability to manufacture, market and sell its products and to generate revenues; the Company's ability to maintain its relationships with key partners and grow relationships with new partners; the Company's ability to maintain or protect the validity of its U.S. and other patents and other intellectual property; the Company's ability to launch and penetrate markets in new locations and new market segments; the Company's ability to retain key executive members and hire additional personnel; the Company's ability to maintain and expand intellectual property rights; interpretations of current laws and the passages of future laws; the Company's ability to achieve greater regulatory compliance needed in existing and new markets; the Company's ability to achieve key performance milestones in its planned operational testing; the Company's ability to establish adequate sales, marketing and distribution channels; security, political and economic instability in the Middle East that could harm its business; and acceptance of the Company's business model by investors. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with the SEC, including, but not limited to, the risks, uncertainties and other factors included in the Company's Annual Report on Form 20-F, filed with the SEC on March 30, 2026. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Pulsenmore or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made, and Pulsenmore undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as otherwise required by law.
Investor Contact:
MiriSegal-Scharia
MS-IR LLC
msegal@ms-ir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/pulsenmore-strengthens-us-commercial-leadership-appoints-med-tech-veteran-david-woods-as-chief-commercial-officer-302906744.html
SOURCE Pulsenmore Ltd.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Who is Pulsenmore's new Chief Commercial Officer?
David Woods has been appointed Chief Commercial Officer of Pulsenmore. He brings more than 25 years of medtech leadership experience and most recently held the same role at Creo Medical.